Clinical trials: Viraemia
CMV Infection, Persistent CMV Viremia
Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
The purpose of this study is to see how well transfusions of T-cells work in treating CMV. Tcells are a type of white blood cell that helps protect the body from infection.
- Trial name
- NCT02136797
- Testing
- CMVpp65 Specific T-cells
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Heart Failure
HCV Positive Heart Donors
Study subjects active on the waiting list for a heart transplant at the NYU Langone Transplant Institute who are hepatitis C (HCV) negative will receive a heart transplant from a donor who tests positive for HCV.
- Trial name
- NCT03382847
- Testing
- Transplant with HCV positive donor, followed by surveillance and treatment of viremia
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- NYU Langone Health
BK Virus (BKV) Viremia
BK Virus Infection (Viremia) Natural History in Renal Transplant Recipients
The objectives of this study is to establish the natural history of BK virus viremia and other possible opportunistic viral pathogens in renal transplants recipients.
- Trial name
- NCT01782209
- Where
- 6 sites in United States
- Volunteers
- 335 people
- Sponsor
- University of Alabama at Birmingham
Cmv Congenital, CMV Viremia
Cytomegalovirus (CMV) Vaccines: Reinfection and Antigenic Variation
The objectives of the protocol are to determine if a structured cognitive-behavioral interventional counseling of pregnant women can limit acquisition of human cytomegalovirus (HCMV) during pregnancy that we believe, will in turn…
- Trial name
- CMV (NCT03443791)
- Testing
- Women Enrolled, Newborns of Female Study Participants
- Where
- Brazil
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
BK Virus Infection
A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients
This clinical research study will test the safety and efficacy of the investigational medication MAU868, compared to a placebo, in patients who have had a kidney transplant who have active BK virus.
- Trial name
- NCT04294472
- Testing
- MAU868
- Where
- 18 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Vera Therapeutics, Inc.
Acute HIV Infection, HIV Infections
HIV Viremia and Persistence in Acutely HIV-Infected Patients Treated With Darunavir/Ritonavir and Etravirine
Purpose: This is a pilot study to evaluate HIV viremia and persistence in acutely HIV infected antiretroviral naïve patients treated with Darunavir/ritonavir and Etravirine Participants: 20 participants, age 18 and older, HIV…
- Trial name
- NCT00855413
- Testing
- Darunavir, Ritonavir, Etravirine
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- University of North Carolina, Chapel Hill
HIV Infections, Hepatitis B
Entecavir Intensification for Persistent HBV Viremia in HIV-HBV Infection
This study will evaluate HIV-HBV infected individuals who have evidence of HBV replication in the blood after taking 48 weeks of more of the HBV active medication tenofovir in combination with emtricitabine or lamivudine.
- Trial name
- NCT00662545
- Testing
- Entecavir with continued standard of care antiretroviral therapy, continued standard of care with tenofovir in addition to emtricitabine or lamivudine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Francisco
West Nile Fever
Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults
The purpose of this study is to determine whether a single subcutaneous injection of ChimeriVax-WN02 vaccine is well tolerated, safe and induces protective antibodies against West Nile Disease.
- Trial name
- NCT00442169
- Testing
- ChimeriVax-WN02 Low Dose, ChimeriVax-WN02 Medium Dose, ChimeriVax-WN02 High Dose
- Where
- 5 sites in United States
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
HIV Infections
Raltegravir Intensification in HIV-infected Patients
The purpose of this study is to determine whether treatment with Raltegravir further decreases HIV viral replication in HAART-suppressed, HIV-infected patients, potentially improving immune response to antiretroviral therapy.
- Trial name
- NCT00631449
- Testing
- Raltegravir
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Francisco
HIV Infections, Viremia
Enhanced Virologic Monitoring for Pregnant and Postpartum Women With HIV
The goal of this study is to learn about supporting pregnant and postpartum women living with HIV with treatment adherence. The investigators will conduct a pilot study of an intervention that includes peer counseling about viral…
- Conditions
- HIV Infections, Viremia, Pregnancy Related
- Trial name
- NCT05845619
- Testing
- Enhanced virologic monitoring
- Where
- 4 sites in Kenya
- Volunteers
- 550 people
- Sponsor
- University of California, San Francisco
Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
This is a multicenter, open-label, single-arm Phase 1B/2 study to assess the safety and efficacy of tabelecleucel in combination with pembrolizumab for the treatment of subjects with platinum-pretreated, recurrent/metastatic…
- Conditions
- Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections, Epstein-Barr Viraemia
- Trial name
- NCT03769467
- Testing
- Tabelecleucel, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 12 people
- Sponsor
- Atara Biotherapeutics
HIV Infection
Pilot Study of Adding Raltegravir (MK-0518) to Antiretroviral Therapy in Patients With Low Level Viremia
The medicines used to treat HIV can suppress but cannot kill all the virus in the body. A small amount of virus remains at low levels in the part of the blood called the plasma.
- Trial name
- NCT00618371
- Testing
- Raltegravir (MK-0518)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Pittsburgh
EBV-induced Lymphomas, EBV-associated Malignancies
Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies
This is a Phase II trial to evaluate the efficacy and safety of human leukocyte antigen (HLA) partially-matched third-party allogeneic Epstein-Barr virus cytotoxic T lymphocytes (EBV-CTLs) for the treatment of EBV-induced…
- Conditions
- EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma
- Trial name
- NCT01498484
- Testing
- EBV-specific T cells (EBV-CTLs)
- Where
- United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Atara Biotherapeutics
EBV Viremia, CMV Viremia
Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients
The aim of our study is to reduce viral (CMV and EBV) transmission from donor to recipient. The discovery that anti-retroviral therapy to mothers with HIV reduced transmission of the virus to their babies was pivotal to the…
- Trial name
- NCT01329185
- Testing
- Valganciclovir
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Minnesota
HIV
Randomized Placebo-Controlled Trial of Atorvastatin in HIV-Positive Patients Not on Antiretroviral Therapy
This study will examine the effects of atorvastatin, a statin (drug that lowers cholesterol) on the human immunodeficiency virus (HIV).
- Trial name
- STATIN (NCT00367458)
- Testing
- Atorvastatin
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Highly-sensitized Kidney Transplant Recipients
Role of Everolimus in Highly Sensitized Patients
A growing number of patients on the kidney transplant waiting list are broadly human leukocyte antigen (HLA) sensitized (HS). These patients are unlikely to have a compatible donor.
- Trial name
- NCT01911546
- Testing
- everolimus + low-dose tacrolimus
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Joseph Kahwaji, MD, MPH
HIV
Emtricitabine/Tenofovir Alafenamide as Salvage ART
Background: HIV attacks the immune system. Antiretroviral therapy (ART) is a combination of drugs used for treating HIV infection. For some people, ART drugs stop working against their HIV.
- Trial name
- NCT02556333
- Testing
- FTC/TAF
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Hepatitis B
Treatment of Persistent Viremia (Virus in Blood) in Chronic Hepatitis B Subjects Already Receiving Adefovir Dipivoxil
This study explores the efficacy, safety and tolerability of tenofovir DF (TDF) 300 mg once daily monotherapy versus the combination of emtricitabine 200 mg plus tenofovir DF 300 mg (FTC/TDF) once daily in subjects currently…
- Trial name
- NCT00307489
- Testing
- tenofovir DF, emtricitabine /tenofovir DF
- Where
- 28 sites in United States, France and 2 more
- Volunteers
- 106 people
- Sponsor
- Gilead Sciences
BK Virus Nephropathy, BK Virus Infection
Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK Viremia
The purpose of this study is to compare Posoleucel (formerly known as ALVR105; Viralym-M) to placebo in kidney transplant recipients who have high or low levels of BK virus in their blood.
- Trial name
- NCT04605484
- Testing
- Posoleucel (formerly known as ALVR105) cells
- Where
- 33 sites in United States
- Volunteers
- 61 people
- Sponsor
- AlloVir
Cytomegalovirus
Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
The purpose of this study is to see how well transfusions of T-cells work in treating CMV. T-cells are a type of white blood cell that helps protect the body from infection.
- Trial name
- NCT01646645
- Testing
- CMV-pp65 CTLs
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Memorial Sloan Kettering Cancer Center